Transform infected revision arthroplasty
Courtesy of Courtesy of Mr Alan Norrish Consultant Orthopaedic Surgeon, Mr Dimitrios Giotikas, Specialist Orthopaedic Surgeon, Addenbrooke’s Hospital, Cambridge, UK
35-year-old male presented with recurrent periprosthetic infection after complex hinged total knee replacement (TKR), performed 1 year ago, to treat severe post-traumatic knee osteoarthritis. 6 months after the initial procedure, he developed periprosthetic infection.
Change of polyethylene, synovectomy, microorganism specific systemic antibiotics and repetitive arthroscopic lavage of the knee failed to control the infection.
Because of the knee stiffness and the compromised soft tissue condition, a revision TKR was not deemed appropriate so decision was made to treat infection with knee fusion.
7 months post-operatively, the infection remained controlled, the bone had consolidated and the patient had returned to daily activities without significant restrictions or symptoms.
2 years post-operatively, no recurrence of infection had occurred.
For indications, contraindications, warnings and precautions see Instructions for Use. The treating physician is responsible for deciding the type and quantity of antibiotic used. Concurrent use of locally administered antibiotics may affect setting time.
The mixing of antibiotics with the STIMULAN Kit / STIMULAN Rapid Cure device is considered off-label usage of the medicinal product. To do so is at the professional risk of the surgeon / healthcare professional.
This page may include the use of STIMULAN or techniques that go beyond the current clearance/ approval granted by the relevant regulatory authority. Please contact your local representative for further information.
©2017, Biocomposites and STIMULAN are registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.
Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710
Patents pending: GB1502655.2, EP 16154210.5, US 15/040075, CN 201610089710.5, US 15/288328.